Skip to main
  1. Stocks
  2. Rocket Pharma
  3. Forecast
RCKT

Rocket Pharma (RCKT) Stock Forecast & Price Target

Rocket Pharma (RCKT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Rocket Pharmaceuticals is viewed positively because its Danon disease program now has clearer pivotal success criteria, and the available Phase I and early Phase II data show durable biologic activity with all six evaluable Phase I patients meeting responder criteria at 12 months and five of six remaining transplant-free at 58 months. The company also improved its financial flexibility by securing up to $150 million from Hercules Capital, including $35 million drawn at closing, which extends its runway into 3Q28 from 2Q28 and can be lengthened further by additional tranches. Fundamentally, the stock’s appeal is supported by a large underdiagnosed market of roughly 10,000 to 11,000 U.S. patients, plus more than $1 billion in potential peak revenue in the initial indication and over $2 billion with broader Danon expansion.

Bears say

Rocket Pharmaceuticals is viewed cautiously because it remains an early commercial-stage company with one approved product that is not yet generating revenue, while the majority of its pipeline is still clinical stage and exposed to regulatory and manufacturing setbacks. The outlook is further pressured by continuing cash burn, a runway into 3Q28 that may not extend through launch, and an expectation that additional Hercules draws or equity financing will be needed, potentially on dilutive or restrictive terms. On top of this, the RP-A501 clinical hold, the possibility of longer and more capital-intensive pivotal trials, and intense competition heighten execution risk and could delay commercialization or weaken future pricing power.

Rocket Pharma (RCKT) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rocket Pharma and is not a guaranteed prediction by Public.com or investment advice.

Rocket Pharma (RCKT) Analyst Forecast & Price Prediction

Get the latest Rocket Pharma (RCKT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Rocket Pharma (RCKT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rocket Pharma (RCKT) Forecast

Analysts have given Rocket Pharma (RCKT) a Buy based on their latest research and market trends.

According to 7 analysts, Rocket Pharma (RCKT) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rocket Pharma (RCKT)


Rocket Pharma (RCKT) Analyst Forecast & Price Prediction

Get the latest Rocket Pharma (RCKT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Rocket Pharma (RCKT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RCKT stock data and trends